Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of MT10109L (NivobotulinumtoxinA) for Glabellar Lines in Japanese Adults
jRCT2031240690Phase 3Recruiting
- Sponsor
- Medytox Inc.
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab + botulinumtoxinA in glabellar furrowing (2 arms), sponsored by Medytox Inc. Primary endpoint: Primary efficacy endpoint. Started May 2025; status: recruiting.
02
Drugs
nivolumab + botulinumtoxinA
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on jRCT2031240690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240690.